Teva Pharmaceutical Industries, Ltd. v. GlaxoSmithKline, LLC

22-37 U.S. Supreme Court Closed 3 patents
Get a prior-art report

Infringement action filed 11 Jul 2022 in the U.S. Supreme Court and closed 15 May 2023, with 3 patents asserted. Recorded basis of termination: petition dismissed.

Case recordPatsnap Litigation Data·

Case record

Case no.
22-37
Verdict cause
Infringement action
Court
U.S. Supreme Court
Court level
Supreme Court
Case region
District of Columbia
Chief judge
None recorded
Trial level
Judicial review
Filed – Closed
11 Jul 2022 – 15 May 2023
Duration
308 days
Basis of termination
Petition Dismissed
Products & marks
Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions · Method of treatment for decreasing mortality resulting from congestive heart failure
Source: Patsnap Litigation Data. Case 22-37, U.S. Supreme Court. Open this record in Eureka
Patsnap Eureka

Check this patent against your own product

Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.

Get an FTO claim chart
10,000 free credits to start
Patent at issue
US5760069A Inactive App. US08/483635

Method of treatment for decreasing mortality resulting from congestive heart failure

A method of treatment using a compound of Formula I:(I) wherein: R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R3 is hydrogen or lower alkyl of up to 6 carbon atoms; R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent -CH2-O-; X is a valency bond, -CH2, oxygen or sulfur; Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl; R5 and R6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a -CONH2- group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R5 and R6 together represent methylenedioxy; or a pharmaceutically acceptable salt thereof, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and digoxin for decreasing mortality resulting from congestive heart failure (CHF) in mammals, particularly humans.

Read claims and description in Eureka
Patent standing
Legal status
Inactive
Granted
2 Jun 1998
Est. expiry
7 Jun 2015
Validity challenges
None recorded
Licences recorded
None recorded
Classification
A61K31/403A61K31/196A61K31/34A61K31/40A61K31/401C07D207/16A61K31/404A61K31/44A61K31/54A61K31/549A61K31/662A61K31/70A61K31/702A61K38/00A61K45/00A61K45/06A61P9/00A61P9/04C07D209/88
Examiner
JARVIS, WILLIAM R. A.
US4503067A Inactive App. US06/479921

Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions

Carbazolyl-(4)-oxypropanolamine compounds of the formula(I) wherein R1 is hydrogen, lower alkanoyl or aroyl; R2 is hydrogen, lower alkyl or arylalkyl; R3 is hydrogen or lower alkyl; R4 is hydrogen or lower alkyl, or when X is oxygen, R4 together with R5 can represent -CH2-O-; X is a valency bond, -CH2-, oxygen or sulfur; Ar is mono- or bicyclic aryl or pyridyl; R5 and R6 are individually selected from hydrogen, halogen, hydroxyl, lower alkyl, aminocarbonyl, lower alkoxy, aralkyloxy, lower alkylthio, lower alkylsulphinyl or lower alkylsulphonyl; R5 and R6 together can represent methylenedioxy; and the salts thereof with physiologically acceptable acids are outstandingly effective in the treatment and prophylaxis of circulatory and cardiac diseases, e.g., hypertension and angina pectoris.

Read claims and description in Eureka
Patent standing
Legal status
Inactive
Granted
5 Mar 1985
Earliest priority
13 Apr 1978
Est. expiry
5 Mar 2007
Validity challenges
None recorded
Licences recorded
None recorded
Classification
C07D209/00C07D209/88C07D317/64C07D317/00A61K31/40A61K31/403A61P9/08A61P25/02C07D401/12C07D405/12
Prosecution counsel
FELFE & LYNCH
Examiner
BRUST, JOSEPH PAUL

Also asserted in this case

1 more

The docket lists 3 asserted patents. Full bibliographic detail, drawings and prosecution history for the remaining asserted patent are one query away in Eureka.

Source: Patsnap patent data + case record. Bibliographic fields and drawings reproduced from the published patent document. Break down the claims
Parties & counsel

Parties of record

Counsel of record

Source: case record + Patsnap company data. Attorney names appear as recorded in the docket. Compare both portfolios
Outcome

Basis of termination

From the record · verbatim

"Petition DENIED"

Case 22-37 · U.S. Supreme Court · closed 15 May 2023
Source: case record, verbatim. The quoted paragraph is the basis-of-termination text as filed.

Related cases

Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.

FAQ

Frequently asked questions

What is case 22-37?

22-37 is a patent infringement action brought by Teva Pharmaceutical Industries, Ltd. against GlaxoSmithKline, LLC, filed on 11 Jul 2022 in the U.S. Supreme Court. The case closed on 15 May 2023.

Which patents were asserted in 22-37?

US5760069A (“Method of treatment for decreasing mortality resulting from congestive heart failure”), assigned to SB PHARMCO PUERTO RICO INC., currently inactive; US4503067A (“Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions”), assigned to ROCHE DIAGNOSTICS GMBH, currently inactive; USRE40000E1 (“Method of treatment for decreasing mortality resulting from congestive heart failure”), assigned to SMITHKLINE BEECHAM (CORK) LIMITED. The record also lists Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions and Method of treatment for decreasing mortality resulting from congestive heart failure.

How was case 22-37 terminated?

The recorded basis of termination is petition dismissed. The termination text reads: "Petition DENIED"

How long did case 22-37 take?

308 calendar days, from filing on 11 Jul 2022 to closure on 15 May 2023.

Who were the attorneys and the judge in 22-37?

Jaime Ann Santos and William McGinley Jay are recorded as counsel for plaintiff Teva Pharmaceutical Industries. Juanita R. Brooks appears for defendant GlaxoSmithKline.

Answers reproduce fields from the case record for 22-37 and do not constitute legal advice. Ask your own question

Disclaimer. This page reproduces publicly available court docket data for case 22-37 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.

Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.

No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.

No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.